Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? - Test2 - elhamkhani - TriplyDB

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

http://www.wikidata.org/entity/Q33589472

about

Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research Osteoporosis Treatment: When to Discontinue and When to Re-start Prevention and treatment of bone changes associated with exposure to glucocorticoids Bisphosphonate drug holiday: choosing appropriate candidates Does salmon calcitonin cause cancer? A review and meta-analysis Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study.A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring UK clinical guideline for the prevention and treatment of osteoporosis Design, synthesis, and osteogenic activity of daidzein analogs on human mesenchymal stem cells.Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Patient perceptions of osteoporosis treatment thresholds Effect of self-referral on bone mineral density testing and osteoporosis treatment Increase in the serum parathyroid hormone level during a bisphosphonate drug holiday.Clinician's Guide to Prevention and Treatment of Osteoporosis Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis.Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.Risk of atypical femoral fracture during and after bisphosphonate use.The effects of the Korean reference value on the prevalence of osteoporosis and the prediction of fracture risk.Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.Bone Mesenchymal Stem Cells with Growth Factors Successfully Treat Nonunions and Delayed Unions The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials.Screening Tests for Osteoporosis: Too Few for Some, Too Many for Others.Eleven years of experience with bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type I Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday.The Impact of Oral Hygiene Maintenance on the Association Between Periodontitis and Osteoporosis: A Nationwide Population-Based Cross Sectional Study.Prevalence of Fracture Risk Factors in Postmenopausal Women Enrolled in the POSSIBLE US Treatment Cohort.Bisphosphonate drug holiday: who, when and how long.Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films.Decayed, Missing, and Filled Teeth Index and Periodontal Health in Osteoporotic Patients Affected by BRONJ: An Observational Study.Gender- and age-related treatment compliance in patients with osteoporosis in Germany.Use of combination therapy in the treatment of primary osteoporosis: protocol for a network meta-analysis of randomised trials Bisphosphonates and atypical subtrochanteric fractures of the femur.The Malaysian Clinical Guidance on the management of postmenopausal osteoporosis, 2012: a summary.Bone health and human immunodeficiency virus infection.Safety concerns with the long-term management of osteoporosis.

P2860

Q26771713-A0B94D49-D888-4711-B7A5-AC77870EBC45 Q26782621-CFD7F1FB-3197-4A38-B38B-D8031126AEEC Q26858980-A03820EE-8F80-4CF6-BE5A-DE5F8BBC94F5 Q26861474-AD91F490-F7BB-4DA1-A171-2B5AD0D54EA3 Q27004682-F2222BBA-5979-431F-8914-DBE7BBFE1911 Q28084816-44D463F5-1F4B-4CA0-8E65-AD7A4C358996 Q30978614-435B35BB-5D41-4CCA-8954-75E9B049AEDE Q31155466-4B85405C-7770-4A58-8E4B-7BA4D17B6B00 Q33570209-D85E1CB7-4965-487B-A414-85568EFFFDA7 Q33581078-8BA866EE-28B3-4EE4-9DF2-DB72A26F3CFC Q33636493-126EBCDB-ADEF-4E42-B7BE-FB9E4A594800 Q33715141-2A25A9EB-5E44-4260-99F9-B07ACCD2B518 Q33766971-DC763EA3-8451-41B3-8C00-117DCDD7D099 Q33911512-89D159C0-862F-44DE-B6F7-72AB24C6E0C3 Q34219208-E2FAF70B-8033-4D04-B247-C7A1D2BDFB6B Q34250632-985FDB56-8470-48D7-938C-F4E4B08E2B23 Q34375420-9BBBAC01-8C49-43CB-9D59-1A5580E9B7F7 Q34553469-6AAA09E1-E1F0-4264-AD71-45D91529E69A Q35033184-41C08D4E-1D63-4B7B-AEEF-9DE2D90A4C13 Q35197628-AB928955-40A5-4826-9B5A-270D061EB5F2 Q35245940-47A7FF5B-3684-4CB5-B13E-0334FCDA2E99 Q35536507-7E4B44C2-AC90-43E7-A8A8-B58355910DA8 Q35783281-51253ACD-4C69-4BEE-AE92-FB9D2A71062B Q36215878-D5DB1FDB-F143-44EF-92ED-4947ECA09974 Q36258463-57F9B89F-C466-4535-A770-D5224439AB63 Q36500182-510416AE-BEC5-4CF1-B316-AF2A571B6839 Q36523054-6B1C742F-4C83-4F53-B764-879DB9BF2E53 Q36580804-048E09E1-977F-490E-ABEF-02AC3D82AE4D Q36766167-B521BDFE-DCD3-4910-93BF-03C0E3CCDFB0 Q36999714-2B442325-EA9D-4F45-BAA9-2B080F298B79 Q37018032-2838DDD3-60BC-472D-ACBB-CBC3D6B90D39 Q37135281-D12395BF-B081-4494-A178-F51C9BC5F664 Q37392009-BBDA5272-1C7F-43A2-8C61-C3695310E565 Q37422398-73E79F77-2E91-4459-AE1D-B797E16CCA4B Q37446418-B5E7B554-ED29-4AC8-882A-C6D1C5C9BB0C Q37454589-CB57FA2B-58F3-47A7-B1A4-507FD6FBA902 Q37733851-51554FE4-2DA1-433D-8592-23AE11025CF3 Q38084690-FE05C331-46D5-4130-AD08-1455201AF9BD Q38095828-C0B216BD-4F8D-4C80-A8F2-E824860080A4 Q38101363-6E1D3B2D-156A-4013-9C8F-598B9C0DF45A

P2860

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

http://www.wikidata.org/entity/Q33589472

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

@ast

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

@en

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

@nl

type

label

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

@ast

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

@en

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

@nl

prefLabel

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

@ast

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

@en

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

@nl

P1433

Q33589472-83CDF2EB-1F9D-4A7D-A3A6-B0CB0EF64A05

P1476

Q33589472-4361E372-71DE-40EB-9B19-D4C77E5A054E

P2093

Q33589472-132AA6BD-B06D-4635-B208-B4F52533A525

Q33589472-6C8A75AE-6A59-4AAB-A7A4-7CFF7BA1C809

Q33589472-8EB82EFC-827C-4C8B-808C-03174CB20C48

Q33589472-98A825F8-15F0-4F16-82DD-3D2E40C6DB5F

Q33589472-A62D80B8-31E3-47CA-B455-A1E557C13321

P2860

Q33589472-369337F7-BCB3-4EBB-9C9D-A2F27DDAD1F4

Q33589472-428D794D-7FAB-4891-8F34-A56516687663

Q33589472-DAF28BFB-4D6F-46D0-95B6-67A208EF72BA

P304

Q33589472-CB40845F-89AC-4BD7-AD40-F4A8A1D98F62

P31

Q33589472-DAC40106-6BE9-427E-9C40-D22D15101826

P356

Q33589472-77D40952-D0F8-4D23-8D3E-77F0ADA0BCFB

P407

Q33589472-8BCF1671-6D6F-43B4-95BB-4D2EA4163B09

P433

Q33589472-92F89D5F-02F9-4505-BC18-240A02FB4080

P478

Q33589472-56148F4F-AFFC-4605-B472-51BFFB8A5369

P577

Q33589472-8672EFB9-9FE5-4DF4-A48A-283F271F1BF8

P698

Q33589472-18C229BB-F89B-4F8E-85A7-88782B2A2680

P921

Q33589472-0458BD6E-569F-4119-9B92-5D6DA581F0A5

P932

Q33589472-5ABC1056-56A6-4D9B-9123-A973A202DCA6

P356

P1433

The New England Journal of Medicine

P1476

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

@en

P2093

Ann V Schwartz

http://www.w3.org/2001/XMLSchema#string

Clifford J Rosen

http://www.w3.org/2001/XMLSchema#string

Dennis M Black

http://www.w3.org/2001/XMLSchema#string

Douglas C Bauer

http://www.w3.org/2001/XMLSchema#string

Steven R Cummings

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.

P304

2051-2053

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMP1202623

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

366

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22571169

http://www.w3.org/2001/XMLSchema#string

P921

P932

4015798

http://www.w3.org/2001/XMLSchema#string